[The Effects of Thymosin alpha1 on Immune Function of Mice after Skin Transplantation].

Chen Y, Lu HM, Guo Q, Hu WM

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition1 Nov 2015

PMID26867314PepBankPUB-26867314

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, Tal alone lowered IL-1 compared with untreated controls at 1, 7, 14 and 21 days.
In plain wordsIn mice with skin grafts, thymosin alpha‑1 alone lowered IL-1 compared with untreated mice.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-1 level after skin transplantation
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Untreated control (Group A)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731401
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, Tal alone lowered IL-2 compared with untreated controls at 1, 7, 14 and 21 days.
In plain wordsIn mice with skin grafts, thymosin alpha‑1 alone lowered IL-2 compared with untreated mice.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-2 level after skin transplantation
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Untreated control (Group A)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731402
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, Tal alone lowered IL-6 compared with untreated controls at 1, 7, 14 and 21 days.
In plain wordsIn mice with skin grafts, thymosin alpha‑1 alone lowered IL-6 compared with untreated mice.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-6 level after skin transplantation
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Untreated control (Group A)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731403
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, Tal alone lowered IL-17 compared with untreated controls at 1, 7, 14 and 21 days.
In plain wordsIn mice with skin grafts, thymosin alpha‑1 alone lowered IL-17 compared with untreated mice.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-17 level after skin transplantation
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Untreated control (Group A)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731404
05AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, Tal alone raised IL-10 compared with untreated controls at 1, 7, 14 and 21 days.
In plain wordsIn mice with skin grafts, thymosin alpha‑1 alone raised IL-10 compared with untreated mice.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-10 level after skin transplantation
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Untreated control (Group A)
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731405
06AnimalAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, cytokine levels did not differ significantly between the Tal group and the CsA group.
In plain wordsIn mice with skin grafts, cytokine levels with thymosin alpha‑1 alone did not differ from those with cyclosporin A alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeCytokine levels, Tal versus CsA
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
400 microg/kg · intraperitoneal injection · 21 dAs given in this study (mouse).
Source sentences
Summary
While no statistical significance shows between Group B and C.
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
Report a problemFND-2686731406

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal lowered IL-1 compared with CsA alone and Tal alone.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 lowered IL-1 compared with either drug alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-1 level, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA alone and Tal alone (pooled)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731407
08AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal lowered IL-2 compared with CsA alone and Tal alone.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 lowered IL-2 compared with either drug alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-2 level, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA alone and Tal alone (pooled)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731408
09AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal lowered IL-6 compared with CsA alone and Tal alone.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 lowered IL-6 compared with either drug alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-6 level, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA alone and Tal alone (pooled)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731409
10AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal lowered IL-17 compared with CsA alone and Tal alone.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 lowered IL-17 compared with either drug alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseIL-17 level, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA alone and Tal alone (pooled)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731410
11AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal raised IL-10 compared with CsA alone and Tal alone.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 raised IL-10 compared with either drug alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-10 level, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
CsA alone and Tal alone (pooled)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After transplantation, in 1, 7, 14, 21 d, the cytokine of Group B, C and ID compared to Group A, as well as Group D to B&C respectively, shows a decreaing of IL-1, IL-2, IL-6, IL-17 value and increasing of IL-10 significantly (P<0.05) at the same time point; While no statistical significance shows b…
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731411
12AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal gave a higher CD4/CD8 ratio than the other groups.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 gave a higher CD4/CD8 ratio than the other groups.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD4/CD8 ratio, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Other groups
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Compared with other groups, Group D have a high ratio of CD4/CD8, and a high percentage of CD4+ CD25+ T cells (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731412
13AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with allogeneic skin grafts, the combination of CsA and Tal gave a higher percentage of CD4+CD25+ T cells than the other groups.
In plain wordsIn mice with skin grafts, cyclosporin A plus thymosin alpha‑1 gave a higher share of CD4+CD25+ T cells than the other groups.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD4+CD25+ T cell percentage, combination of CsA and Tal
Study
mousen: not reported in source
C57 to BALB/c allogeneic skin transplantation
Comparator
Other groups
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Compared with other groups, Group D have a high ratio of CD4/CD8, and a high percentage of CD4+ CD25+ T cells (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Group A, control group (without any treatment, n=20); Group B, CsA treatment group (CsA 10 mg/kg, n=20); Group C, Tal treatment group (Tal 400 microg/kg, n=20) and Group D, combination therapy group (CsA 10 mg/kg & Talphal 400 microg/kg, n=20).
Summary · context
In the three experimental group, the drug of each group were respectively administrated by intraperitoneal injection daily, for 21 d.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-2686731413

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.